Conjugation
Cy5
Gene ID number
7048
Additional conjugation
Cy5.5
Modification site
Tyr259
Swiss Prot
P37173
Subcellular location
Cytoplasm
Tested applications
IF(IHC-P)
French translation
anticorps
Clonality
Polyclonal
Concentration
1ug per 1ul
Immunogen_range
250-270/567
Target Antigen
TGFBR2 Tyr259
Excitation Emission
625,650nm/670nm
Modification
Phosphorylation
Crossreactivity
Human, Mouse, Rat
Recommended dilutions
IF(IHC-P)(1:50-200)
Clone
Polyclonal antibody
Category
Conjugated Primary Antibodies
Host Organism
Rabbit (Oryctolagus cuniculus)
Purification method
This antibody was purified via Protein A.
Long name
TGFBR2 Tyr259 Polyclonal Antibody , Cy5 Conjugated
Specificity
This is a highly specific antibody against TGFBR2 Tyr259.
Crossreactive species details
Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.
Source
KLH conjugated synthesised phosphopeptide derived from human TGF beta Receptor II around the phosphorylation site of Tyr259
Storage conditions
Keep the antibody in an aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store refrigerated at 2 to 8 degrees Celcius for up to 1 year.
Synonyms
AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TGFR-2; TGFbeta-RII; TGF-beta receptor type-2; TGF-beta type II receptor; Transforming growth factor-beta receptor type II; TGF-beta receptor type II; TbetaR-II; TGFBR2
Properties
If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.Cy5 antibodies are excited by the 650-nanometer wave of an argon laser and detected at a 670-nanometer captor.
Antigen background
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.